 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Stockwinners Market Radar for July 04, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
| DXCM | Hot Stocks08:57 EDT DexCom says Health Canada approved Dexcom G7 - Dexcom announced that Health Canada has approved the next-generation Dexcom G7 Continuous Glucose Monitoring System for people with all types of diabetes, ages two years and older. Dexcom G7 is not yet available for purchase. Dexcom Canada is working to bring Dexcom G7 to Canadians living with diabetes by the end of 2023, the company said in a statement.
|
| BKNG | Hot Stocks08:21 EDT Booking.com does not meet Digital Markets Act criteria by deadline - Booking Holdings' Booking.com confirmed that it "remains engaged in constructive discussions" with the European Commission on the applicability of the Digital Markets Act to its business. The company added, "With respect to the July 3, 2023 deadline for companies to notify as to whether they fall under the gatekeeper presumption under the DMA, Booking.com has determined that due to the negative impact of COVID-19 on its business, it does not meet the criteria set out in the regulation and as a result the regulation does not require the submission of a formal notification. This has been communicated to and discussed with the European Commission. The company expects that these thresholds will likely be met at the end of 2023, in which case the company would expect to notify the European Commission of that fact within the required deadlines."
|
| PTGX JNJ | Hot Stocks08:20 EDT Protagonist says JNJ-2113 met efficacy endpoints in psoriasis study - Protagonist Therapeutics (PTGX) announced topline results from the Phase 2b FRONTIER 1 clinical trial evaluating the oral interleukin-23 receptor antagonist JNJ-2113 in adult patients with moderate-to-severe plaque psoriasis. The trial achieved all primary and secondary efficacy endpoints. JNJ-2113 is being developed by Johnson & Johnson's (JNJ) Janssen Biotech under Protagonist's license and collaboration agreement with Janssen. A greater proportion of patients who received JNJ-2113 achieved PASI 75 as well as PASI 90 and PASI 100 compared to placebo, at week 16, the company said in a statement. Trial results for JNJ-2113 demonstrated a profile that supports its advancement into Phase 3 clinical development for moderate-to-severe plaque psoriasis in adult patients, it added.
|
